FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.
Pricing for FOXO4-DRI
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
Average price
$19.50/mg
range $6.40–$50.00/mg
Sellers
36
from $75.00
45-day trend
+4.9%
vs 45-day avg $/mg
34 of 36 sellers have a current price· 25 stale listings hidden (not seen in 7 days)
Top Merit pick
🇺🇸 Glacier Aminos99✓ verified at source · just now
$13.50/mg -30.8% vs avg$135
10mg
- 🇺🇸 BioLongevity Labs96
via Disclosed Labs · just now
$27.50/mg +41% vs avg$275
10mg
- 🇺🇸 Ion Peptide95
✓ verified at source · just now
$11.90/mg -39% vs avg$119
10mg
100.0% purity 1 COA - 🇺🇸 Orbitrex Peptides95
via Disclosed Labs · just now
$19.00/mg -2.6% vs avg$190
10mg
no purity - 🇺🇸 Peptide Tech94
✓ verified at source · 1d ago
$15.00/mg -23.1% vs avg$150
10mg
- 🇺🇸 Verified Peptides86
via Disclosed Labs · just now
$22.00/mg +12.8% vs avg$220
10mg
99.7% purity 3 COAs - 🇺🇸 Simple Peptide85
via Disclosed Labs · just now
$18.00/mg -7.7% vs avg$180
10mg
- peptidetech.isUnscored
via Disclosed Labs · just now
$15.00/mg -23.1% vs avg$150
10mg
no purity - realpeptides.coUnscored
via Disclosed Labs · just now
$30.00/mg +53.9% vs avg$300
10mg
no purity
Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.
COAs for FOXO4-DRI
20 third-party tests across 9 vendors. Each card links to the full report.
For
FOXO4-DRI
by Verified Peptides· batch FOX062602108
For
FOX04-DRI
by Ion Peptide· batch FOX10-04022026
For
FOXO4-DRI
by BioLongevity Labs· batch 261153
For
FOXO4-DRI
by Peptidology· batch 1671
For
FOX04-DRI
by Real Peptides
For
FOXO4-DRI
by Skye Peptides· batch FOX26-15-001
For
FOXO4-DRI
by Ascension Peptides· batch 55-01260229
For
FOXO4-DRI
by Ascension Peptides· batch 55-01260229
For
FOXO4-DRI
by Glacier Aminos· batch FOX10GA01
For
FOXO4-DRI
by Kimera Chems· batch KC-FX4-GRY1
For
FOXO4-DRI
by Verified Peptides· batch 03-25-0110A
For
FOX-04
by Simple Peptide· batch cmp9xk4yj00329trx7cgpf22y
For
FOXO4-DRI
by Peptide Tech· batch F4D-5195
For
FOXO4-DRI
by BioLongevity Labs· batch cmojb7f8i01b6kirxq6ddannn
For
FOXO4-DRI
by Kimera Chems· batch Black Cap
For
FOXO4-DRI
by BioLongevity Labs· batch cmojb7qk401dukirxq2vhxw8n
Purity not on file
For
FOX04-DRI
by Real Peptides
Purity not on file
For
FOXO4-DRI
by Skye Peptides· batch FOX26-15-001
Purity not on file
For
FOXO4-DRI
by Peptide Tech· batch F4D-5195
Purity not on file
For
FOXO4-DRI
by Verified Peptides· batch 03-25-0110A
12 citations indexed for FOXO4-DRI
review · 2026
Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline
Cellular senescence, driven by the interaction between FOXO4 and p53, is increasingly recognized as a crucial mechanism in brain aging and the development of neurodegenerative disorders.
Study · 2026
Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence
Temozolomide (TMZ) is still the first-line drug for glioblastoma (GBM) treatment though tumor cell resistance remains a major challenge.
review · 2026
The right time, the right cell: the potential for precision senotherapy in pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a fatal vasculopathy driven by proinflammatory signaling that leads to pulmonary vascular remodeling and ultimately, right ventricular failure. Existing therapies fail to eliminate dysfunctional cells or reverse pathologic remodeling.
animal · 2025
FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway
Objectives Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking.
Study · 2025
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
A central process contributing to the phenotype of aging is cellular senescence. We recently identified the FOXO4 - p53 axis as pivotal in maintaining the viability of senescent cells, and that senescent cells can be targeted selectively with the senolytic peptide FOXO4-DRI.
Study · 2025
FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
Keloids are pathological scars exhibiting tumour-like aggressiveness and high recurrence rate.